Vanguard Group Inc Onconova Therapeutics, Inc. Transaction History

Vanguard Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$0.57 - $1.0 $967 - $1,697	-1,697 Reduced 0.24%	706,921 $417,000
Q2 2023 Aug 14, 2023	BUY	$0.67 - $1.42 $57,160 - $121,145	85,314 Added 13.69%	708,618 $836,000
Q4 2022 Feb 10, 2023	BUY	$0.63 - $0.97 $217 - $335	346 Added 0.06%	623,304 $405,000
Q3 2022 Nov 14, 2022	BUY	$0.95 - $1.45 $105,416 - $160,899	110,965 Added 21.67%	622,958 $549,000
Q2 2022 Aug 12, 2022	BUY	$1.04 - $1.9 $29,503 - $53,901	28,369 Added 5.87%	511,993 $676,000
Q1 2022 May 13, 2022	SELL	$1.46 - $2.82 $529,563 - $1.02 Million	-362,715 Reduced 42.86%	483,624 $890,000
Q4 2021 Feb 14, 2022	SELL	$2.49 - $3.73 $33,791 - $50,619	-13,571 Reduced 1.58%	846,339 $2.16 Million
Q3 2021 Nov 12, 2021	BUY	$3.81 - $6.76 $683,102 - $1.21 Million	179,292 Added 26.34%	859,910 $3.29 Million
Q2 2021 Aug 13, 2021	BUY	$6.28 - $16.2 $4.27 Million - $11 Million	680,618 New	680,618 $4.72 Million

276K

Ticker ONTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,895,600
Market Cap $12.3M
Description
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.